ArticlemSphere2026
Rapid Cas13a-based
Thi Hai Yen Nguyen, Sakshi Garg, Gordon Adams, Sreekar Mantena, Nisha Gopal, Ho-Jun Suk, Jeffrey D Klausner, Pardis C Sabeti, Jacob E Lemieux, Lao-Tzu Allan-Blitz
Abstract read
In one paragraphArticle in mSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Thi Hai Yen NguyenDivision of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Sakshi GargDivision of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Gordon AdamsDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Sreekar MantenaBroad Institute of Massachusetts Institute of Technology and Harvard, Boston, Massachusetts, USA.
Nisha GopalBroad Institute of Massachusetts Institute of Technology and Harvard, Boston, Massachusetts, USA.
Ho-Jun SukDxLab Inc., Somerville, Massachusetts, USA.
Jeffrey D KlausnerDepartment of Population and Public Health Sciences, Keck School and Medicine, USC, Los Angeles, California, USA.
Pardis C SabetiBroad Institute of Massachusetts Institute of Technology and Harvard, Boston, Massachusetts, USA.ORCID 0000-0002-9843-1890 Jacob E LemieuxDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Lao-Tzu Allan-BlitzDivision of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-4077-3476 Funding
Medical Scientist Training ProgramT32GM144273 · NIGMS · HARVARD MEDICAL SCHOOL · PI David Shumway Jones, Jacqueline A. Lees · 2022 to 2026
$14.7MThe development & pilot implementation of a CRISPR-based low-cost point-of-care assay for detecting Neisseria gonorrhoeae and molecular markers of antimicrobial resistance in resource-limited settingsK23AI182453 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Lao-Tzu Allan-Blitz · 2024 to 2026
$585kBrigham Research InstituteHearst Family FoundationNHLBI NIH HHS K23AI182453NIGMS NIH HHS T32 GM144273
6 · The paper itselfAbstract
Antimicrobial resistance in IMPORTANCE: Antimicrobial resistance in
Indexed as
Anti-Bacterial AgentsBacterial ProteinsCefiximeGenotyping TechniquesNeisseria gonorrhoeaeDrug Resistance, BacterialGenotypeGonorrheaHumansMicrobial Sensitivity TestsRapid Diagnostic TestsThird Generation CephalosporinsAnti-Bacterial AgentsBacterial ProteinsCefiximeThird Generation Cephalosporinsantimicrobial resistanceCas13cefiximeCRISPRNeisseria gonorrhoeaepoint-of-careresistance-guided therapy
Identifiers
PMID42153664
PMCPMC13317185
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390